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TO THE EDITOR
Melanoma incidence has been rising
steadily in fair-skinned populations
around the world, with most of the
increase due to greater numbers of thin
lesions being diagnosed (Welch et al.,
2005; Coory et al., 2006; Gimotty et al.,
2007). Melanoma mortality has also
been rising, albeit less rapidly com-
pared with incidence (Welch et al.,
2005; MacKie et al., 2007). Survival
from melanoma is strongly correlated
with tumor thickness; patients with thin
lesions (p1 mm) have a 20-year survival
approaching 96%, whereas thicker
lesions confer substantially higher risks
of premature mortality (Balch et al.,
2009; Green et al., 2012). On the
basis of these prognostic associations,
there is a widespread perception that the
majority of deaths from melanoma result
from thick lesions. However, data
describing population distributions of
lethal melanomas by thickness have
been seldom reported (Criscione and
Weinstock, 2010) and may have been
biased by missing thickness data (Shaikh
et al., 2013). Such analyses are
important for understanding where the
burden of melanoma mortality lies and
would serve to inform melanoma con-
trol strategies. We therefore performed
an analysis of melanoma incidence and
mortality in Queensland, Australia, the
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jurisdiction with the world’s highest
rates of this malignancy.
Notification of cancer to the Queens-
land Cancer Registry (QCR) has been
legally mandated since 1982, and
reporting of melanoma has been near
complete since 1990. We obtained a
de-identified data set of all melanoma
diagnoses in Queensland from 1990 to
2009, including notifications of all peo-
ple whose underlying cause of death
(ICD-O-3) was cutaneous melanoma. (If
a person was diagnosed with melanoma
before that date, but subsequently died,
their diagnostic details are recorded in
the QCR.) The study was approved by
the QCR prior to data linkage and
release. For each person who died from
melanoma, we obtained information on
their sex, age group, and month and
year of death. We also obtained linked
information on any prior melanoma
diagnoses, including year of notifica-
tion, thickness, histology, and anatomic
site. Using these data, we calculated
age-standardized incidence and mortal-
ity rates for each year for all melanomas
and by thickness of the first primary
(p1, 1.01–2, 2.01–4, and 44 mm).
For the primary mortality analysis, we
included all melanoma decedents and
assumed that the first primary was
lethal. This assumption, although rea-
sonable, is contestable; hence, we
repeated the mortality analyses after
excluding those patients who had more
than one primary melanoma.We used
SAS (version 9.2; SAS Institute, Cary,
NC) for all analyses.
From 1990 to 2009, 4,218 Queens-
land residents died from cutaneous mel-
anoma (67% males; 33% females;
Table 1). Overall, 22% of patients with
lethal melanomas first presented with
metastatic disease, 68% presented with
a single primary lesion, and 10% had
multiple primary melanomas. Thin mel-
anomas (p1 mm) accounted for 19% of
melanoma deaths overall (68% of all
melanomas) but increased from 14% in
1990–1994 to 23% in 2005–2009.
Thus, in the most recent period (2005–
2009), more melanoma deaths in
Queensland were attributable to thin
tumors (p1 mm, 23% of deaths; 68%
of all melanomas) than thick tumors
(44 mm, 14% of deaths; 3% of all
melanomas) or metastatic presentations
(16% of deaths; 3% of all melanomas).
The patterns of mortality by thickness
category were essentially unchanged
when we restricted the analyses to those
with only one primary melanoma noti-
fication (data not shown). As expected,
the intervals from diagnosis to death
were significantly shorter for thicker
tumors than for thinner tumors (Table 2).
Because thickness information was
missing for nearly 10% of melanomas,
we repeated the analyses after imputing
melanoma thicknesses for those patients
with missing data. We imputed thick-
nesses on the basis of distributions
of patients with lethal melanomas of
known thickness using age, sex, histo-
logical type, anatomic site, time period,
and time from diagnosis to death as
potential predictors. Including imputed
thickness data made negligible differ-
ence to the patterns reported above
(Supplementary Table S1 online).
These data, from a population with a
very high incidence of melanoma and a
long history of melanoma education,
Table 1. Incidence and mortality of melanoma in the Queensland population 1990–2009, by thickness
Characteristic
1990–1994 1995–1999 2000–2004 2005–2009
n (%)1 ASR (95% CI) n (%) ASR (95% CI) n (%) ASR (95% CI) n (%) ASR (95% CI)
Incidence
p1 mm 4,796 (64.2) 34.5 (33.5–35.5) 6,797 (67.4) 42.7 (41.7–43.8) 8,272 (69.3) 45.9 (44.9–46.9) 9,376 (68.0) 44.9 (44.0–45.9)
1.01–2.00 mm 1,005 (13.5) 7.4 (7.0–7.9) 1,250 (12.4) 8.0 (7.6–8.5) 1,521 (12.7) 8.5 (8.0–8.9) 1,882 (13.6) 9.1 (8.7–9.5)
2.01–4.00 mm 559 (7.5) 4.3 (3.9–4.7) 735 (7.3) 4.9 (4.5–5.2) 943 (7.9) 5.3 (5.0–5.7) 1,106 (8.0) 5.4 (5.0–5.7)
44 mm 286 (3.8) 2.2 (2.0–2.5) 414 (4.1) 2.8 (2.5–3.1) 478 (4.0) 2.7 (2.5–3.0) 642 (4.7) 3.1 (2.9–3.4)
Metastasis only 351 (4.7) 2.6 (2.3–2.9) 385 (3.8) 2.5 (2.3–2.8) 366 (3.1) 2.0 (1.8–2.3) 391 (2.8) 1.9 (1.7–2.1)
Unknown 475 (6.8) 3.5 (3.2–3.9) 511 (5.1) 3.3 (3.0–3.6) 364 (3.0) 2.1 (1.9–2.3) 393 (2.8) 1.9 (1.7–2.1)
Total 7,472 10,092 11,944 13,790
Mortality
p1 mm 112 (14.0) 0.94 (0.60–1.28) 169 (17.3) 1.06 (0.72–1.40) 219 (19.3) 1.20 (0.85–1.55) 296 (22.7) 1.41 (1.05–1.77)
1.01–2.00 mm 126 (15.8) 0.92 (0.58–1.27) 153 (15.7) 0.97 (0.64–1.30) 194 (17.1) 1.06 (0.73–1.39) 272 (20.8) 1.30 (0.95–1.64)
2.01–4.00 mm 138 (17.3) 1.04 (0.68–1.40) 167 (17.1) 1.09 (0.74–1.44) 212 (18.7) 1.17 (0.82–1.52) 267 (20.4) 1.28 (0.94–1.63)
44 mm 90 (11.3) 0.69 (0.40–0.99) 129 (13.2) 0.85 (0.54–1.16) 165 (14.5) 0.93 (0.62–1.24) 186 (14.2) 0.89 (0.61–1.18)
Metastasis only 207 (25.9) 1.52 (1.09–1.96) 251 (25.7) 1.62 (1.19–2.05) 243 (21.4) 1.34 (0.97–1.70) 207 (15.9) 0.98 (0.68–1.27)
Unknown 126 (15.8) 0.95 (0.60–1.29) 107 (11.0) 0.71 (0.43–0.99) 104 (9.2) 0.58 (0.34–0.82) 78 (6.0) 0.37 (0.19–0.56)
Total 799 976 1,137 1,306
Abbreviations: ASR, age-standardized rates (United States population year 2000); CI, confidence interval.
Data source: Queensland Cancer Registry, 1982–2011 extract.
Invasive melanoma, all ages combined.
Generated on 15 July 2014.
1Totals may not sum up to 100.0% because of rounding.
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show that an increasing proportion of
melanoma deaths occurred among
patients who were diagnosed originally
with thin tumors. Indeed, more people
died from thin melanomas (p1 mm)
than died from thick melanomas
(44 mm) in the most recent reporting
period, raising questions about the opti-
mum strategy for stemming melanoma
mortality.
Two complementary approaches have
been pursued for melanoma control,
namely primary prevention and early
detection. Whereas primary prevention
strategies aim to reduce sun exposure
and thereby reduce overall melanoma
incidence, early detection strategies seek
to educate patients and doctors to iden-
tify suspicious lesions, with the aim of
reducing morbidity and mortality. Wide-
spread early detection is thought to
underlie the shift toward higher inci-
dences of thin melanoma reported in
Australia (Coory et al., 2006; Baade
et al., 2012), the United States, (Geller
et al., 2013), and to some extent Europe
(de Vries et al., 2004). However, there
are concerns that the emphasis on skin
examinations has contributed to the
rapidly rising incidence of thin mela-
nomas through the phenomenon of
overdiagnosis (Burton and Armstrong,
1994; Welch et al., 2005).
The findings here underscore the
dilemma posed by early detection stra-
tegies when applied to the population,
which attempt to strike a balance
between the potential lethality of thin
melanomas on the one hand (as demon-
strated by these data) and the burden of
overdiagnosis on the other. These data
demonstrate that thin melanomas com-
prise a substantial fraction of the overall
burden of lethal melanomas in the high
incidence population of Queensland.
Table 2. Characteristics of melanoma decedents in the Queensland population 1990–2009
Characteristic 1990–1994 (n¼ 799) 1995–1999 (n¼976) 2000–2004 (n¼ 1,137) 2005–2009 (n¼1,306) Total (n¼4,218)
Age at death (years) n (%) n (%) n (%) n (%) n (%)
o30 39 (4.9) 50 (5.1) 55 (4.8) 49 (3.8) 193 (4.6)
30–39 70 (8.8) 81 (8.3) 70 (6.2) 86 (6.6) 307 (7.3)
40–49 124 (15.5) 118 (12.1) 146 (12.8) 146 (11.2) 534 (12.7)
50–59 122 (15.3) 172 (17.6) 191 (16.8) 217 (16.6) 702 (16.6)
60–69 191 (23.9) 195 (20.0) 232 (20.4) 244 (18.7) 862 (20.4)
70–79 181 (22.7) 223 (22.9) 265 (23.3) 325 (24.9) 994 (23.6)
80þ 72 (9.0) 137 (14.0) 178 (15.7) 239 (18.3) 626 (14.8)
Sex
Male 539 (67.5) 633 (64.9) 789 (69.4) 888 (68.0) 2,849 (67.5)
Female 260 (32.5) 343 (35.1) 348 (30.6) 418 (32.0) 1,369 (32.5)
Number of primary melanomas
1 546 (68.3) 647 (66.3) 764 (67.2) 922 (70.6) 2,879 (68.3)
2 36 (4.5) 61 (6.3) 100 (8.8) 123 (9.4) 320 (7.6)
3 7 (0.9) 12 (1.2) 25 (2.2) 32 (2.5) 76 (1.8)
4þ 3 (0.4) 5 (0.5) 5 (0.4) 22 (1.7) 35 (0.8)
Metastasis only 207 (25.9) 251 (25.7) 243 (21.4) 207 (15.9) 908 (21.5)
Body site of first primary melanoma
Head/neck 134 (16.8) 146 (15.0) 200 (17.6) 267 (20.4) 747 (17.7)
Trunk 210 (26.3) 267 (27.4) 347 (30.5) 370 (28.3) 1,194 (28.3)
Upper limbs 110 (13.8) 145 (14.9) 162 (14.3) 216 (16.5) 633 (15.0)
Lower limbs 124 (15.5) 155 (15.9) 171 (15.0) 229 (17.5) 679 (16.1)
Not specified 14 (1.8) 12 (1.2) 14 (1.2) 17 (1.3) 57 (1.4)
Metastasis only 207 (25.9) 251 (25.7) 243 (21.4) 207 (15.8) 908 (21.5)
Median (25%, 75%) duration between first melanoma diagnosis and death by thickness of first primary
p1mm 5 (3–6) 6 (3–9) 7 (3–11) 7 (4–13) 6 (3–10)
1.01–2.00 mm 4 (2–6) 4 (3–7) 4 (2–8) 5 (2–8) 4 (2–7)
2.01–4.00 mm 2 (1–5) 3 (2–5) 3 (2–5.5) 3 (2–6) 3 (2–5)
44 mm 2 (1–3) 2 (1–4) 4 (2–6) 2 (1–3) 2 (1–4)
Unknown 2 (1–4) 2 (1–5) 3 (1–9) 4.5 (1–15) 3 (1–7)
Metastasis only 1 (0–2) 1 (0–1) 1 (0–2) 1 (0–2) 1 (0–2)
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The earlier US study also reported that a
high proportion of fatal melanomas were
attributable to thin melanomas (27%)
(Criscione and Weinstock, 2010). More-
over, the proportion of deaths attributable
to thin melanomas in Queensland is
rising. Such a distribution, although
entirely concordant with the respective
trends in incidence and case fatality of
thin and thick melanomas, is arguably
not widely appreciated. Interestingly, and
in contrast to the Queensland experience,
was the observation in the SEER data that
the proportion of deaths attributable
to thick melanomas increased over the
observation period (Criscione and
Weinstock, 2010).
Although early detection strategies
should continue, clinicians must be
mindful that thin melanomas contribute
substantially to overall melanoma mor-
tality, notwithstanding their overall favor-
able prognosis. Identifying the clinical
and molecular features of thin melano-
mas that confer poor prognosis should be
the focus of continued research. From a
public health perspective, it can be
argued that primary prevention activities
aimed at reducing the occurrence of
melanoma in the entire population
should be accorded a very high priority.
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TO THE EDITOR
Chronic pain and itch are substantial
quality-of-life obstacles for patients with
the genetic skin disorder recessive dys-
trophic epidermolysis bullosa (RDEB).
RDEB is caused by loss-of-function
mutations in the anchoring fibril protein
type VII collagen. Extreme skin fragility
leads to chronic wounds and inflamma-
tion that are accompanied by significant
pain and itch. Itchy skin has been
consistently rated as the highest burden
in RDEB patients (van Scheppingen
et al., 2008; Danial et al., 2014), and
another study found that 93% of dystro-
phic EB patients experienced itch
symptoms (Snauwaert et al., 2014).
Compounding the burden of itching in
RDEB, scratching can be associated
with new lesions and secondary infec-
tion, exacerbating the disease’s symptoms
and undermining treatment.
The second-highest burden in RDEB
is pain (van Scheppingen et al., 2008;Accepted article preview online 28 November 2014; published online 18 December 2014
Abbreviations: ECM, extracellular matrix; ENF, epidermal nerve fiber; JEB, junctional epidermolysis
bullosa; MC, mast cell; PGP9.5, protein gene product 9.5; PNS, peripheral nervous system; RDEB,
recessive dystrophic epidermolysis bullosa; SNP, subepidermal neural plexus
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